India has come up as a reliable healthcare destination with steadily expanding coverage and improving expertise.
CAGR in in-patient market over 2015-20.
healthcare markets in terms of incremental growth by 2020.
FDI allowed under automatic route for greenfield projects.
Government investment over the period 2017-18 to 2019-20.
aims to provide annual healthcare coverage of nearly US$7,000 per family, benefiting more than 500 million vulnerable people.
diagnostics market expected by 2022, based on a CAGR of 20.4% from US$5bn in 2012.
annual growth in India's healthcare technology startup space, where AI, IoT and data analytics are put to use for innovation solutions.
The Indian medical tourism industry, currently valued at around US$3bn, is expected to touch US$8bn by 2022.
expected valuation of India’s wellness and traditional healthcare industry by 2020, from the current US$10bn valuation.
worth od diagnostics industry in India is with the share of the organized sector being almost 25% in this segment (15% in labs and 10% in radiology).
worth of primary care industry with the share of the organized sector being practically negligible.
India is home to diverse range of medicinal plants which have been used for centuries by the local people to meet not only their own primary health care needs but also to address ailments of domesticated animals (Pashuayurveda) & crops.
Though AYUSH systems of medicine are popular and progressively a large section of population uses these systems for health care, there is lack of awareness among the general public about remedies available in these systems.
The revamped Schemes would be applicable to the Social Infrastructure domain including Healthcare, Education and Water Treatment. 30% of the Total Project Cost is to be taken up by the Central Government.
+91 124 4382629
India has a well-oiled enterprise promoting machinery that is backed by strong legislative, judiciary, executive and capital establishments
American drugmaker Merck operates a manufacturing plant in India.
French drugmaker Sanofi operates a manufacturing plant in Goa.
UK's GlaxoSmithKline operates R&D and manufacturing in India.
Singapore's 4CE Ventures has invested in Indian health tech startups.
India has a well-oiled enterprise promoting machinery that is backed by strong legislative, judiciary, executive, and capital establishments